Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update Post published:March 2, 2021 Post category:Press Release
Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation Post published:February 18, 2021 Post category:Press Release
Numinus Wellness Completes Acquisition of Montreal-based Mindspace Wellbeing Post published:February 8, 2021 Post category:Press Release
Numinus Wellness Closes Q1 2021 with Strong Cash Position and Industry Firsts Post published:January 29, 2021 Post category:Press Release
Numinus Wellness Forges Forward into Psychedelic Discovery Research with the Orbitrap Exploris 120 Mass Spectrometer Post published:January 13, 2021 Post category:Press Release
Numinus Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic Products Post published:January 6, 2021 Post category:Press Release
Numinus Announces Closing of $17 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option Post published:December 29, 2020 Post category:Press Release
Numinus Completes First Extraction of its Psilocybe Mushrooms Post published:December 17, 2020 Post category:Press Release